Top Markets
Coin of the day
GBS Inc. GBS Inc.

GBS Inc.

GBS
Clasificación en acciones #33711
Operating across North America and the Asia-Pacific region, GBS Inc.... Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Precio por acción
$0.4732
Última sincronización: 2022-10-26
Capitalización bursátil
$7.05M
Cambio (1 día)
-0.03%
Cambio (1 año)
0.00%
País
US
Comercio GBS Inc. (GBS)

Categoría

Historial de rendimiento por dividendo de GBS Inc. (GBS)
Rendimiento por dividendo (TTM) de GBS Inc. (símbolo bursátil: GBS) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de GBS Inc. (GBS) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras